New 'Sandwich' strategy aims to stop leukemia relapse after CAR t therapy
NCT ID NCT05470777
First seen May 28, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase 2 trial tests a combination of two types of CAR T-cells (targeting CD22 and CD19) followed by a stem cell transplant using the patient's own cells, then more CAR T-cells—a 'sandwich' approach—to prevent relapse in B-cell acute lymphoblastic leukemia. The study includes 37 patients who cannot or choose not to have a donor transplant. The goal is to see if this strategy is safe and improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD22/CD19 CAR T-cells and autologous stem cell transplant
What this could lead to
If successful, this approach could lower the chance of leukemia returning after CAR T therapy, offering a more durable remission without needing a donor transplant.
What could go wrong
This is a small, early-phase study (37 people) with no control group, so results may not apply broadly. Risks include severe immune reactions, infections, and the possibility that the cancer still relapses.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.